179 related articles for article (PubMed ID: 30804155)
1. Metastatic calcinosis cutis due to refractory hypercalcaemia responsive to denosumab in a patient with multiple sclerosis.
Jorge A; Szulawski R; Abhishek F
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30804155
[TBL] [Abstract][Full Text] [Related]
2. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
Størling L; Villadsen GE; Krogh K; Vestergaard P
Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
[TBL] [Abstract][Full Text] [Related]
3. Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia.
Li Y; Fan CY; Manni A; Simonds WF
BMJ Case Rep; 2020 Apr; 13(4):. PubMed ID: 32350052
[TBL] [Abstract][Full Text] [Related]
4. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
5. Metastatic calcinosis cutis in a patient with Hodgkin's lymphoma.
Dennin MH; Dulmage BO; Yazdan P; Keimig E
Dermatol Online J; 2018 Nov; 24(11):. PubMed ID: 30695977
[TBL] [Abstract][Full Text] [Related]
6. Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution.
Marcus JF; Shalev SM; Harris CA; Goodin DS; Josephson SA
Arch Neurol; 2012 Jan; 69(1):129-32. PubMed ID: 22232355
[TBL] [Abstract][Full Text] [Related]
7. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
8. Extensive calcinosis cutis in relapsed acute lymphoblastic leukaemia.
Tan AW; Ng HJ; Ang P; Goh YT
Ann Acad Med Singap; 2004 Jan; 33(1):107-9. PubMed ID: 15008575
[TBL] [Abstract][Full Text] [Related]
9. Utility of denosumab therapy in management of severe hypercalcaemia caused by primary hyperparathyroidism - Case report with review of literature.
Jadhao P; Mangaraj S
J R Coll Physicians Edinb; 2023 Jun; 53(2):104-108. PubMed ID: 36825782
[TBL] [Abstract][Full Text] [Related]
10. Uncommon localization of calcinosis cutis after liver transplantation.
Neau-Cransac M; Lepreux S; Labreze C; Quinart A; Revel P; Saric J; Bioulac-Sage P
Dermatology; 2005; 211(4):379-81. PubMed ID: 16286755
[No Abstract] [Full Text] [Related]
11. Calcinosis cutis and Sjögren's syndrome.
Llamas-Velasco M; Eguren C; Santiago D; García-García C; Fraga J; García-Diez A
Lupus; 2010 May; 19(6):762-4. PubMed ID: 20156928
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
13. Self-healing dystrophic calcinosis following trauma with transepidermal elimination.
Pitt AE; Ethington JE; Troy JL
Cutis; 1990 Jan; 45(1):28-30. PubMed ID: 2298040
[TBL] [Abstract][Full Text] [Related]
14. Calcinosis cutis with siliconomas complicated by hypercalcemia.
Loke SC; Leow MK
Endocr Pract; 2005; 11(5):341-5. PubMed ID: 16191496
[TBL] [Abstract][Full Text] [Related]
15. Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy.
Del Barrio-Díaz P; Moll-Manzur C; Álvarez-Veliz S; Vera-Kellet C
Br J Dermatol; 2016 Sep; 175(3):608-11. PubMed ID: 26799451
[TBL] [Abstract][Full Text] [Related]
16. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
17. Normocalcemic primary hyperparathyroidism presenting as calcinosis cutis.
Sepriano AR; Pereira Pombo de Araújo FC; Mourão de Almeida Lourenço Dias PM; da Cunha Branco J
J Clin Rheumatol; 2014 Sep; 20(6):330-1. PubMed ID: 25160019
[No Abstract] [Full Text] [Related]
18. Systemic sclerosis and calcinosis cutis: response to rituximab.
Poormoghim H; Andalib E; Almasi AR; Hadibigi E
J Clin Pharm Ther; 2016 Feb; 41(1):94-6. PubMed ID: 26667314
[TBL] [Abstract][Full Text] [Related]
19. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
20. Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy.
Nachankar A; Katyal A; Bansal N; Bishnoi A
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35803612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
